NEW YORK, NY--(Marketwire - Dec 12, 2012) - IsoRay, Inc. (NYSE MKT: ISR), a developer, manufacturer and seller of isotope-based medical products and devices, has recently announced their patented Cesium-131 sutured seeds and seed sutured mesh has resulted in impressive early results for both metastatic brain cancer and meningioma tumors, two of the most common forms of brain cancer and tumors.

GlobalData Brain Tumor - Drug Pipeline Analysis and Market Forecast to 2016 shows the market at a little over $1 billion in 2009 and forecasts growth at a CAGR of 3.1% to reach $1.3 billion by 2016. An increasing amount of novel therapies are expected to launch in this period and this will act as a significant driver for the market. 

GlobalData expects major pharmaceutical companies like Pfizer (NYSE: PFE), Merck (NYSE: MRK) and Novartis AG (NYSE: NVA) to lead the competition, but in an article from ibtimes.com, the trend is that big pharmaceutical companies reach out into partnerships to keep their own R&D costs to a minimum, which could be a trend that drives the brain tumor treatment market.

For more information, please visit www.isoray.com

This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Information, opinions and analysis contained herein are based on sources deemed to be reliable and are subject to change without notice. A third party has hired and paid Equity Spotlight one thousand two hundred and ninety five dollars for the publication and circulation of this news release. Accordingly, certain information included herein may be forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. However, no representation, expressed or implied, is made as to the accuracy, completeness or correctness. In light of the above, we accept no liability for any losses arising from an investor's reliance on or use of this report. We do not and have not had any ownership interest in said third party of any kind.